Bloomberg biotech reporter Doni Bloomfield sat down with Intellia CEO Nessan Bermingham about what he thinks is unique about Crispr, the gene-editing technique the drugmaker -- among others in the field -- is using to tackle disease.

producer: Anne Mostue +1-617-210-4662 or amostue@bloomberg.net.

Running time 05:23

a

Play Episode

Before it's here, it's on the Bloomberg Terminal. LEARN MORE